Posted by Michael Wonder on 08 Oct 2018
SMC - October 2018 decisions
8 October 2018 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice accepting four new medicines.
Gemtuzumab ozogamicin (Mylotarg) was accepted for the treatment of acute myeloid leukaemia following consideration through the SMC’s Patient and Clinician Engagement (PACE) process, which is used for medicines that treat end of life and very rare conditions.
Anakinra (Kineret) was accepted for the treatment of Still’s disease, a rare type of inflammatory arthritis that is similar to rheumatoid arthritis. Still’s disease may begin during childhood as systemic juvenile idiopathic arthritis or in adulthood as adult onset Still’s disease.
